Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Yaxley, William; McBean, Rhiannon; Wong, David; Grimes, David Robert; Vasey, P.; Frydenberg, Mark; Yaxley, John

doi:10.4111/icu.20210097

Cited by 5 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, treated with PSMA-RLT, other retrospective studies showed that patients with only lymph node metastases (LNM) lived longer than patients with bone, lung, and liver metastases [39,40]. Treated with PSMA-RLT, docetaxel (DOC)-naïve LNM patients lived longer free of PSAR than LNM patients who had failed to DOC [41].…”

Section: Discussionmentioning

confidence: 99%

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer

von Eyben,

Virgolini,

Baum

2024

Preprint

View full text Add to dashboard Cite

Background: In 2021, two randomized controlled trials (RCTs), TheraP and VISION, demonstrated that 177Lu-PSMA-617 as monotherapy was more effective for enhancing the decline of PSA than the comparator third-line treatments. Methods: Our review summarizes new RCTs that add to the use of radioligand therapy (RLT) for patients with high-risk prostate cancer (PCa). Results: Five past and present RCTs include 1139 patients. A RCT, ENZA-p, studied first-line treatment of patients with metastatic castration-resistant PCa (mCRPC). A combination of enzalutamide (ENZA) and 177Lu-PSMA-617 gave longer progression-free survival than ENZA as monotherapy. Other RCTs of patients with mCRPC, including the PSMAfore, and SPLASH trials, showed 177Lu-PSMA-617 as second-line treatment gave better progression-free survival than androgen receptor pathway inhibitors (combined p value 6 x 10-8). Conclusion: Patients with PCa may gain if they are given PSMA-RLT early in the treatment of PCa and as part of combination therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer

von Eyben,

Virgolini,

Baum

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Some studies have suggested the possibility of early adoption of 177 Lu-PSMA therapy, taking advantage of better initial conditions of crPC patients, naïve to chemotherapy, or prior to surgery. [168,169]. However, resistance can occur sometimes.…”

Section: Radioligand Therapy Of Advanced Prostate Cancermentioning

confidence: 99%

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives

Volpe,

Nappi,

Piscopo

et al. 2023

Cancers

View full text Add to dashboard Cite

Prostate cancer is the most frequent epithelial neoplasia after skin cancer in men starting from 50 years and prostate-specific antigen (PSA) dosage can be used as an early screening tool. Prostate cancer imaging includes several radiological modalities, ranging from ultrasonography, computed tomography (CT), and magnetic resonance to nuclear medicine hybrid techniques such as single-photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. Innovation in radiopharmaceutical compounds has introduced specific tracers with diagnostic and therapeutic indications, opening the horizons to targeted and very effective clinical care for patients with prostate cancer. The aim of the present review is to illustrate the current knowledge and future perspectives of nuclear medicine, including stand-alone diagnostic techniques and theragnostic approaches, in the clinical management of patients with prostate cancer from initial staging to advanced disease.

show abstract

PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects

Parghane

Basu

2023

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Cited by 5 publications

References 22 publications

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives

PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects

Contact Info

Product

Resources

About